Therapeutic options for carbapenemase-producing Enterobacteriaceae.

January 26, 2017 at 3:32 pm

Rev Esp Quimioter. 2015 Sep;28 Suppl 1:12-5.

[Article in Spanish]

Salgado P, Gilsanz F, Maseda E1.

Author information

1Emilio Maseda, Servicio de Anestesia y Reanimación, Hospital Universitario La Paz; Paseo de la Castellana 261, 2846, Madrid, Spain. emilio.maseda@gmail.com

Abstract

Carbapenemase-producing Enterobacteriaceae (CPE) has spread worldwide becoming a threat to public health. However, no randomized clinical trials about the efficacy of optimizing antibiotic treatment have been published. Experimental studies have been designed to find combinations of antibiotics with synergistic activity.

Their main aim has been increasing the speed of bacterial destruction and decreasing resistance. The latest guidelines recommend combination therapy. The carbapenems has been chosen as the basis of such therapy.

We face limited therapeutic options. Polymyxins, fosfomycin and gentamicin have reemerged in this context, becoming the basis of multiple combination regimens, with beneficial effects both in vitro and in murine models of infection.

PDF

http://seq.es/seq/0214-3429/28/sup1/salgado.pdf

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Biología Molecular, Epidemiología, Health Care-Associated Infections, Infecciones nosocomiales, Metodos diagnosticos, Resistencia bacteriana, REVIEWS, Sepsis, Update.

The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients? Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.


Calendar

January 2017
M T W T F S S
« Dec   Feb »
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Most Recent Posts


%d bloggers like this: